Historical abbv News Stories
AbbVie’s Big Deals and $100B U.S. Investment Boost
This week AbbVie announced two landmark oncology licensing deals (Zelgen and RemeGen), reported robust full‑year 2025 results with $61.16B revenue, and committed $100B to U.S. R&D and capital investment tied to a voluntary pricing agreement—concrete moves that materially affect ABBV stock outlook.
AbbVie Builds U.S. API Hubs, Raises $7.5B Debt Now!
AbbVie announced a $380M investment to expand API manufacturing in North Chicago and launched a $7.5B senior notes offering to refinance upcoming debt. These concrete moves — combined with mixed Q4 results driven by Humira strength and Rinvoq softness — reshape ABBV's operational and financial outlook for investors.
AbbVie Q4: Skyrizi & Rinvoq Drive 2026 Outlook Now
AbbVie's Q4/FY2025 results show continued strength from Skyrizi and Rinvoq, lifting immunology and neuroscience sales even as aesthetics lag. Management issued clear 2026 adjusted EPS guidance; near-term shares retraced modestly on low volume.
AbbVie Boosts U.S. Ties with $100B Investment Deal
AbbVie stock climbed on heavy volume after the company struck a voluntary $100 billion U.S. investment agreement and continued to benefit from immunology patent protections. These moves strengthen manufacturing footholds, regulatory optics, and revenue durability for ABBV shareholders.
AbbVie Q4 Beat, Stock Drops on Humira Risk
AbbVie reported a modest Q4 beat (EPS $2.71 vs $2.65; revenue $16.62B vs $16.41B) but shares fell ~3.8% as investors focused on Humira erosion and mixed performance from growth brands. Elevated trading volume and limited new regulatory catalysts leave ABBV exposed to pipeline execution and pricing pressures despite Rinvoq’s prior GCA approval.